Tests once-daily oral cannabis against placebo for weight loss
Tests daily oral cannabis against placebo in adults with obesity.
Key facts
- Who runs it
- Joshua A. Lile, Ph.D.
- Where
- Lexington, United StatesSee the site
- Trial code
- Registry title
- Cannabis for Obesity Trial
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 5 Aug 2026
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Cannabis
- Placebo
- Record updated
- 7 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity who are otherwise in good health. It tests once-daily oral cannabis against placebo for weight loss.
- Age
- 18 to 65 years
- Sex
- Men and women
- Disease stage
- Obesity with a BMI of 30 kg/m2 or higher, in good health, with weight that has been stable over the past 3 months (no change greater than 5 kg (11 lb))
- Earlier treatment
- No anti-obesity medication in the past 90 days (stable metformin is allowed). No current use of cannabis or CBD, and no more than 15 lifetime uses of cannabis.
- Biomarker or test result
- Blood pressure and pulse within set ranges (systolic 90 to 140 mmHg, diastolic 50 to 90 mmHg, pulse 50 to 100 bpm), and a negative test for cannabinoids at screening
Main reasons for not taking part
- Current insulin treatment or a history of type 1 diabetes
- Stomach or intestinal surgery that could change how oral drugs are absorbed
- Significant psychiatric disorder, or current use of psychiatric medications
- Pregnant, breast-feeding, or planning pregnancy; or not using highly effective contraception
- History of heart failure or arrhythmias, or a heart attack, stroke or unstable angina in the past 3 months
The registry criteria, word for word
Show all 35 criteriaShow less
Who can take part
- Male or female
- Age 18-65 years
- BMI >=30 kg/m2 (i.e., obese)
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory evaluations at Screening and/or Check-in as assessed by one of the MD study personnel
- Able to speak and read English
- Apple or Android phone, or Android tablet with wi-fi or cellular service
- Vital signs at Screening and Check-in as per the following ranges and stable (measured in a supine position after a minimum of 5 minutes of rest):; Systolic blood pressure ≥ 90 and ≤ 140 mmHg; Diastolic blood pressure ≥ 50 and ≤ 90 mmHg; Pulse rate ≥ 50 and ≤ 100 bpm
Who cannot take part
- Use of any anti-obesity medication in the past 90 days. Specifically GLP-1 agonists (e.g., liraglutide, semaglutide, tirzepatide), SGLT-2 inhibitors (e.g., canagliflozin, dapagliflozin, empagliflozin, ertugliflozin), sulfonylureas (e.g., glimepiride, glipizide), medlitinides (e.g., repaglinide, nateglinide), Contrave, phentermine (alone or combination product such as Qsymia) or Orlistat. Stable use of metformin is permitted
- Current treatment with insulin
- History of stomach or intestinal surgery or resection for obesity or otherwise (such as gastric bypass, sleeve-gastrectomy, bowel or small bowel resection) that would potentially alter absorption and/or excretion of orally administered drugs (uncomplicated appendectomy, cholecystectomy, and hernia repair > 6 months prior to Screening will be allowed)
- Current use of medications associated with hemodynamic instability (e.g., amphetamines, other sympathomimetic agents, atropine, scopolamine, other anticholinergic agents)
- Current use of medications that are inhibitors of CYP2C9 (e.g., amiodarone, fluconazole) or CYP3A4 enzymes (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin, grapefruit juice)
- Any clinically important uncontrolled illness, medical/surgical procedure, or major trauma within 8 weeks prior to dose administration on Day 1
- Current use of any medications or supplement which would either compromise the validity of the study or the safety of the participant
- History of type 1 diabetes
- Obesity secondary to a known genetic, endocrine, or medical condition, such as polycystic ovarian syndrome, hypothyroidism, Cushing's syndrome, growth hormone deficiency, insulinoma, hypothalamic disorders (e.g., Froelich syndrome, Bardet-Biedl syndrome, Prader-Willi syndrome)
- Moderate or Severe Substance Use Disorder according to DSM-5 criteria; urine test positive for recent use of an abused drug
- History of significant psychiatric disorder (e.g., bipolar, schizophrenia, depression, history of panic attacks)
- Current use of psychiatric medications (e.g., antipsychotics, antidepressants, anxiolytics)
- Current or past year history of one or more of the following disorders associated with overeating: rumination disorder, bulimia nervosa, severe/extreme binge eating disorder (>7 episodes per week) or other specified/unspecified feeding/eating disorder that would increase risk to the participant or complicate interpretation of the data. Individuals who report mild to moderate (<7 episodes per week) binge eating disorder are eligible
- History of congestive heart failure or arrhythmias
- Any of the following cardiovascular events in the past 3 months; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina
- History of significant hypersensitivity, intolerance, or allergy to a cannabinoid or "gummy" product
- History of seizure or predisposing factors for seizure (head trauma resulting in unconsciousness in past six months or CNS tumors)
- Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in an investigator's opinion, might jeopardize the participant's safety or compliance with the protocol
- Lab-Screening Exclusion:; Thyroid-stimulating hormone (TSH) level outside of the normal range, confirmed on repeat testing; AST, ALT, or alkaline phosphatase >2x ULN; EGFR <60 ml/min as calculated using the Cockroft-Gault equation
- UK Students cannot participant
- Current cannabis use (e.g., past month; negative test for cannabinoids during screening) and no more than 15 self-reported lifetime uses
- Self-reported current use of CBD
- Severe past negative experience with cannabis or cannabinoid use (e.g., panic attack, anxiety)
- Stable body weight over the past 3 months. No changes greater than 5 kg
- A score of 15 or more on the Patient Health Questionnaire (PHQ-9)
- Female participant who is pregnant, breast-feeding, or intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method
- Male participant who is not using a highly effective contraceptive method or who has a female partner who is not using a highly effective contraceptive method
- Meeting the following criteria from the Columbia Suicide Severity Rating Scale (C-SSRS):; "yes" to Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or; "yes" to Question 5 (Active Suicidal Ideation with Specific Plan and Intent) or; "yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) and; the ideation or behavior occurred within the past month
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- University of KentuckyLexington, United StatesContact: Joshua Lile, PhDTaking people
About the trial
What the trial wants to find out
The goal of this study is to determine the initial efficacy of once daily oral cannabis for weight loss in obese individuals.
The 2 groups in the trial
- ActiveTreatment being tested
Cannabis "gummy", starting at 5 mg THC and increased every three weeks by 5 mg increments up to a maximum target dose of 15 mg THC, administered once daily for duration of 6-month trial participation.
Treatment: Cannabis
- PlaceboPlacebo, for comparison
Placebo cannabis "gummy", containing no active THC, administered once daily for duration of 6-month trial participation.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Placebo-Controlled Clinical Trial of Once Daily Oral Cannabis for Weight Loss in Obese Individuals
- Plain-language title
- Tests once-daily oral cannabis against placebo for weight lossGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06137365, who can take part
- Record updated
- 7 August 2026